Procter & Gamble Health - Public Comps and Valuation Multiples

Procter & Gamble Health Overview

About Procter & Gamble Health

Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company’s distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.

Founded

1967

HQ

Employees

1.3K+

Website

pghealthindia.com

Sectors

Health & Beauty
Nutraceuticals & Cosmeceuticals
BioTech

Financials

LTM Revenue $130M

LTM EBITDA $34.5M

EV

$1.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Procter & Gamble Health Financials

As of September 2025, Procter & Gamble Health reported last 12-month revenue of $130M and EBITDA of $34.5M.

In the same period, Procter & Gamble Health generated $92.6M in LTM gross profit and $25.2M in net income.

See Procter & Gamble Health valuation multiples based on analyst estimates

Procter & Gamble Health P&L

In the most recent fiscal year, Procter & Gamble Health reported revenue of $127M and EBITDA of $34.0M.

Procter & Gamble Health expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Procter & Gamble Health valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$130M	XXX	$127M	XXX	XXX	XXX
Gross Profit	$92.6M	XXX	$86.8M	XXX	XXX	XXX
Gross Margin	71%	XXX	68%	XXX	XXX	XXX
EBITDA	$34.5M	XXX	$34.0M	XXX	XXX	XXX
EBITDA Margin	27%	XXX	27%	XXX	XXX	XXX
EBIT	$33.2M	XXX	$31.5M	XXX	XXX	XXX
EBIT Margin	26%	XXX	25%	XXX	XXX	XXX
Net Profit	$25.2M	XXX	$22.7M	XXX	XXX	XXX
Net Margin	19%	XXX	18%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Procter & Gamble Health including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $130M. EBITDA for the last twelve months was $34.5M. In the most recent fiscal year, Procter & Gamble Health achieved $127M in revenue and $34.0M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$130M	Analyst estimates available to subscribers	$127M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$92.6M	Analyst estimates available to subscribers	$86.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	71.3% gross margin	Analyst estimates available to subscribers	68.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$34.5M	Analyst estimates available to subscribers	$34.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	26.6% EBITDA margin	Analyst estimates available to subscribers	26.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$33.2M	Analyst estimates available to subscribers	$31.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	25.6% EBIT margin	Analyst estimates available to subscribers	24.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$25.2M	Analyst estimates available to subscribers	$22.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	19.4% net profit margin	Analyst estimates available to subscribers	17.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Procter & Gamble Health

This financial data table provides comprehensive performance metrics for Procter & Gamble Health, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Procter & Gamble Health generated $130M in revenue over the last twelve months.
The company achieved $34.5M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $92.6M.
Net income over the last twelve months reached $25.2M.

Fiscal Year Performance

In the most recent fiscal year, Procter & Gamble Health reported $127M in total revenue.
Fiscal year EBITDA was $34.0M.
The company maintained a gross profit margin of 68.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 26.7%.
Net profit margin reached 17.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Procter & Gamble Health. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Procter & Gamble Health Stock Performance

Procter & Gamble Health has current market cap of INR 104B (or $1.2B), and EV of INR 102B (or $1.2B).

Market Cap Evolution

Procter & Gamble Health Stock Data

As of October 17, 2025, Procter & Gamble Health's stock price is INR 6278 (or $71).

See Procter & Gamble Health trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.2B	$1.2B	XXX	XXX	XXX	XXX	$1.52

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Procter & Gamble Health Valuation Multiples

Procter & Gamble Health's trades at 8.9x EV/Revenue multiple, and 32.8x EV/EBITDA.

See valuation multiples for Procter & Gamble Health and 15K+ public comps

Procter & Gamble Health Financial Valuation Multiples

As of October 17, 2025, Procter & Gamble Health has market cap of $1.2B and EV of $1.2B.

Equity research analysts estimate Procter & Gamble Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Procter & Gamble Health has a P/E ratio of 46.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.2B	XXX	$1.2B	XXX	XXX	XXX
EV (current)	$1.2B	XXX	$1.2B	XXX	XXX	XXX
EV/Revenue	8.9x	XXX	8.9x	XXX	XXX	XXX
EV/EBITDA	33.4x	XXX	32.8x	XXX	XXX	XXX
EV/EBIT	34.7x	XXX	36.1x	XXX	XXX	XXX
EV/Gross Profit	12.5x	XXX	n/a	XXX	XXX	XXX
P/E	46.7x	XXX	50.1x	XXX	XXX	XXX
EV/FCF	58.2x	XXX	50.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Procter & Gamble Health Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Procter & Gamble Health Margins & Growth Rates

Procter & Gamble Health's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $42K for the same period.

Procter & Gamble Health's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Procter & Gamble Health's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Procter & Gamble Health and other 15K+ public comps

Procter & Gamble Health Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	27%	XXX	27%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$42K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	43%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial